Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N132G in the Conserved SDN Motif

Antimicrob Agents Chemother. 2017 Feb 23;61(3):e02510-16. doi: 10.1128/AAC.02510-16. Print 2017 Mar.

Abstract

The substitution N132G in the SDN motif of class A β-lactamases from rapidly growing mycobacteria was previously shown to impair their inhibition by avibactam but to improve the stability of acyl-enzymes formed with clavulanate. The same substitution was introduced in KPC-2 and CTX-M-15 to assess its impact on β-lactamases from Enterobacteriaceae and evaluate whether it may lead to resistance to the ceftazidime-avibactam combination. Kinetic parameters for the inhibition of the β-lactamases by avibactam and clavulanate were determined by spectrophotometry using nitrocefin as the substrate. The substitution N132G impaired (>1,000-fold) the efficacy of carbamylation of KPC-2 and CTX-M-15 by avibactam. The substitution improved the inhibition of KPC-2 by clavulanate due to reduced deacylation, whereas the presence or absence of N132G resulted in the inhibition of CTX-M-15 by clavulanate. The hydrolysis of amoxicillin and nitrocefin by KPC-2 and CTX-M-15 was moderately affected by the substitution N132G, but that of ceftazidime, ceftaroline, and aztreonam was drastically reduced. Isogenic strains producing KPC-2 and CTX-M-15 were constructed to assess the impact of the substitution N132G on the antibacterial activities of β-lactam-inhibitor combinations. For amoxicillin, the substitution resulted in resistance and susceptibility for avibactam and clavulanate, respectively. For ceftazidime, ceftaroline, and aztreonam, the negative impact of the substitution on β-lactamase activity prevented resistance to the β-lactam-avibactam combinations. In conclusion, the N132G substitution has profound effects on the substrate and inhibition profiles of class A β-lactamases, which are largely conserved in distantly related enzymes. Fortunately, the substitution does not lead to resistance to the ceftazidime-avibactam combination.

Keywords: CTX-M-15; KPC-2; avibactam; clavulanate; β-lactamase inhibitor.

MeSH terms

  • Amino Acid Motifs
  • Amino Acid Substitution*
  • Amoxicillin / pharmacology
  • Anti-Bacterial Agents / pharmacology*
  • Azabicyclo Compounds / pharmacology*
  • Aztreonam / pharmacology
  • Ceftaroline
  • Ceftazidime / pharmacology
  • Cephalosporins / chemistry
  • Cephalosporins / pharmacology
  • Clavulanic Acid / pharmacology*
  • Cloning, Molecular
  • Drug Combinations
  • Escherichia coli / genetics*
  • Escherichia coli / metabolism
  • Gene Expression
  • Kinetics
  • Mutation
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism
  • Reverse Genetics
  • Substrate Specificity
  • beta-Lactamases / genetics*
  • beta-Lactamases / metabolism

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Cephalosporins
  • Drug Combinations
  • Recombinant Proteins
  • avibactam, ceftazidime drug combination
  • Clavulanic Acid
  • avibactam
  • Amoxicillin
  • Ceftazidime
  • beta-lactamase CTX-M-15
  • beta-lactamase KPC-2
  • beta-Lactamases
  • nitrocefin
  • Aztreonam